Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a fully-humanized IgG2 monoclonal antibody that binds to human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on the activated T cells. Binding to CTLA-4 results in inhibition of its association with the ligands B7-1 (CD80) and B7-2 (CD86), thereby preventing the downregulation of T-cell activation and inhibition of tumor growth. The original drug is currently undergoing clinical trials for the treatment of several cancers such as melanoma, mesothelioma and non-small cell lung cancer
Biovision | A2163 | Anti-CTLA-4 (Tremelimumab), Human IgG2 Antibody DataSheet
Antibody Target: CTLA-4
Target Alternative Name: CP-675, CP-675,206, CP-675206 clone 11.2.1, CD; GSE; GRD4; ALPS5; CD152; CTLA4; IDDM12; CELIAC3
Tag Line: The biosimilar is a human monoclonal antibody that targets CTLA-4 on activated T-lymphocytes and inhibits the interaction with its ligands CD80 and CD86 and promotes T-cell activation
Category: Biosimilars
Host: Recombinant
Isotype: IgG2, kappa
Species Reactivities: Human
Immunogen Sequence: Human CTLA-4
Accession #: DB11771
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
